ClinicalTrials.gg
Active, not recruitingNCT07118176Updated Oct 20, 2026

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

A Phase 1 interventional study of Computed Tomography and Fludeoxyglucose F-18 in Anal Carcinoma, Bladder Carcinoma and Breast Carcinoma, sponsored by Jonsson Comprehensive Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Primary conditionnone(registry's first term: Anus Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Anus Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Jonsson Comprehensive Cancer Center · Phase 1, Interventional, and Diagnostic

How we know

Updated Oct 20, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.

Read the detailed description

PRIMARY OBJECTIVE:

I. To define the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) in normal and cancer tissues of patients with various malignancies measured by standardized uptake values (SUV).

SECONDARY OBJECTIVE:

I. To assess the 68Ga-FAPI-46 biodistribution correlation with fludeoxyglucose F-18 (18F-FDG) biodistribution and to define the frequency of the following phenotypes (FAP+/ FDG+, FAP-/ FDG+, FAP+/ FDG-, FAP-/ FDG-).

OUTLINE:

Patients receive 68Ga-FAPi-46 intravenously (IV) and then, 20-90 minutes later, undergo PET/CT over 20-50 minutes. Patients may undergo optional 18F-FDG PET/CT on study.

02

Conditions studied

  • Anal Carcinoma
  • Bladder Carcinoma
  • Breast Carcinoma
  • Cervical Carcinoma
  • Cholangiocarcinoma
  • Colorectal Carcinoma
  • Esophageal Carcinoma
  • Gastric Carcinoma
  • Head and Neck Carcinoma
  • Hematopoietic and Lymphatic System Neoplasm
  • Hepatocellular Carcinoma
  • Lung Carcinoma
  • Malignant Adrenal Gland Neoplasm
  • Malignant Brain Neoplasm
  • Malignant Neoplasm of Unknown Primary
  • Malignant Solid Neoplasm
  • Malignant Testicular Neoplasm
  • Malignant Uterine Neoplasm
  • Neuroendocrine Neoplasm
  • Ovarian Carcinoma
  • Pancreatic Carcinoma
  • Penile Carcinoma
  • Pleural Carcinomatosis
  • Primary Peritoneal Carcinoma
  • Prostate Carcinoma
  • Salivary Gland Carcinoma
  • Sarcoma
  • Skin Carcinoma
  • Solitary Fibrous Tumor
  • Thymus Carcinoma
  • Thyroid Gland Carcinoma
  • Thyroid Gland Medullary Carcinoma
  • Urothelial Carcinoma
  • Vaginal Carcinoma
03

In context

Lead sponsor

Jonsson Comprehensive Cancer Center is the lead sponsor of 398 studies on the registry; 66 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with the following suspected or diagnosed cancer types:

    • Adrenal cancer
    • Anal cancer
    • Bladder cancer
    • Brain cancer
    • Breast cancer
    • Cancer of unknown primary (CUP)
    • Cervical cancer
    • Cholangiocarcinoma
    • Colorectal cancer
    • Esophageal cancer
    • Gastric cancer
    • Head and neck cancer
    • Hematologic cancer
    • Hepatocellular carcinoma
    • Lung cancer
    • Medullary thyroid cancer
    • Neuroendocrine neoplasias
    • Ovarian cancer
    • Pancreatic cancer
    • Penile cancer
    • Peritoneal cancer
    • Pleural cancer
    • Prostate cancer
    • Sarcoma
    • Salivary gland cancer
    • Solitary fibrous tumor
    • Skin cancer
    • Testicular cancer
    • Thymus cancer
    • Thyroid cancer
    • Urothelial cancer
    • Uterus cancer
    • Vaginal cancer
  • Patients are ≥ 18 years old at the time of the radiotracer administration
  • Patient can provide written
  • Patient is able to remain still for duration of imaging procedure (up to one hour)

Exclusion criteria

Exclusion Criteria:

  • Patient is pregnant or nursing
  • Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Diagnostic (68Ga-FAPi-46 PET/CT)

    Patients receive 68Ga-FAPi-46 IV and then, 20-90 minutes later, undergo PET/CT over 20-50 minutes. Patients may undergo optional 18F-FDG PET/CT on study.

    Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Radiation: Gallium Ga 68 FAPi-46 · Procedure: Positron Emission Tomography

Interventions

  • ProcedureComputed Tomography

    Undergo PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • OtherFludeoxyglucose F-18

    Given IV

    Also known as: 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18

  • RadiationGallium Ga 68 FAPi-46

    Given IV

    Also known as: (68GA)Ga-FAPI-46, 68Ga-FAPi-46, FAPI-46 GA-68, Gallium-68-FAPI-46

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

06

What researchers measure

Primary outcomes

  1. Biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46)

    Will be evaluated in normal and cancer tissues by standardized uptake values to determine where and to which degree 68Ga-FAPi-46 accumulates in normal and cancer tissues.

    Time frame: Up to 2 years

Secondary outcomes

  1. Fludeoxyglucose F-18 (18F-FDG) biodistribution

    Will assess the correlation between 68Ga-FAPi-46 biodistribution and 18F-FDG biodistribution and define the frequency of the following phenotypes: 68Ga-FAPi-46 (FAP)+/fludeoxyglucose F-18 (FDG)+, FAP-/FDG+, FAP+/FDG-, FAP-/FDG-.

    Time frame: Up to 2 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2025 to primary completion in Jun 2026, 10 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 12, 2025
StartActual
Aug 1, 2025
Primary completionActual
Jun 23, 2026was Sep 2026
CompletionEst.
Sep 7, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 6, 2026→Jun 23, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Sep 6, 2026→Jun 23, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07118176
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Aug 1, 2025
Primary completion
Jun 23, 2026
Completion
Sep 7, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Jeremie Calais
principal investigator · UCLA / Jonsson Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion